Handelsbanken Fonder AB Purchases 734 Shares of ICON Public Limited (NASDAQ:ICLR)

Handelsbanken Fonder AB increased its position in ICON Public Limited (NASDAQ:ICLR) by 4.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 17,964 shares of the medical research company’s stock after buying an additional 734 shares during the period. Handelsbanken Fonder AB’s holdings in ICON Public were worth $5,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Liontrust Investment Partners LLP grew its position in ICON Public by 108.4% in the 3rd quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after purchasing an additional 46,739 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its position in ICON Public by 50.7% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 74,820 shares of the medical research company’s stock worth $21,179,000 after purchasing an additional 25,160 shares during the last quarter. Amalgamated Bank grew its position in ICON Public by 5.8% in the 3rd quarter. Amalgamated Bank now owns 8,438 shares of the medical research company’s stock worth $2,078,000 after purchasing an additional 460 shares during the last quarter. Chartwell Investment Partners LLC grew its position in ICON Public by 16.1% in the 3rd quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock worth $1,712,000 after purchasing an additional 963 shares during the last quarter. Finally, Cullen Investment Group LTD. acquired a new stake in ICON Public in the 4th quarter worth $1,620,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Trading Down 3.0 %

Shares of NASDAQ ICLR opened at $300.08 on Friday. ICON Public Limited has a 1-year low of $181.92 and a 1-year high of $344.77. The company has a market cap of $24.76 billion, a PE ratio of 36.51, a P/E/G ratio of 1.46 and a beta of 1.15. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $318.31 and a two-hundred day moving average of $282.20.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. ICON Public had a net margin of 8.30% and a return on equity of 11.84%. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. As a group, equities analysts expect that ICON Public Limited will post 14.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ICLR has been the topic of several recent research reports. Barclays lifted their target price on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Truist Financial lifted their target price on shares of ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Evercore ISI lifted their target price on shares of ICON Public from $325.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. Robert W. Baird lifted their target price on shares of ICON Public from $345.00 to $362.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Mizuho reiterated a “buy” rating and set a $346.00 target price on shares of ICON Public in a research report on Thursday, April 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, ICON Public currently has an average rating of “Moderate Buy” and an average target price of $319.45.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.